KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Obstetrics and Gynecology / 2018 / Cilt: 15 - Sayı: 4

Ykl-40 and cancer antigen 72-4 as new and promising diagnostic and prognostic markers for endometrial cancer

Endometriyal kanser için yeni ve umut verici tanı ve prognostik belirteçler olarak YKL-40 ve kanser antijen 72-4

Suat KARATAŞ
Veysel SAL
İlker KAHRAMANOĞLU
Fuat DEMİRKIRAN
Tugan BEŞE
Macit ARVAS
Nigar SOFİYEVA
Onur GÜRALP
Hafize UZUN
Sayfa
235–242
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The determination of YKL-40 before surgery may be helpful in the evaluation of the regional lymph nodes.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: To determine the predictive role of serum levels of YKL-40 and cancer antigen (CA) 72-4 in the diagnosis of endometrial cancer (EC).Materials and Methods: Forty-one patients with EC and 21 women with uterine polyps were evaluated between January and December 2015 in aprospective study.Results: Age, body mass index, preoperative serum YKL-40 and CA 72-4 levels were significantly higher in the malignant group compared with the controlgroup.
📊
Temel Bulgular & Veri:Serum YKL-40 levels were significantly higher in patients with superficial myometrial invasion and no lymph node involvement (p=0.042; p=0.004).No relationship between clinicopathologic factors and serum CA 72-4 levels was found.Conclusion: Serum CA 72-4 and YKL-40 levels are increased in women with EC compared with uterine polyps.
💡
Sonuç & Katkı:The determination of YKL-40 before surgery may be helpful in the evaluation of the regional lymph nodes.
🔬Tür:Araştırma Makalesi
📍Kapsam:2015 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: To determine the predictive role of serum levels of YKL-40 and cancer antigen (CA) 72-4 in the diagnosis of endometrial cancer (EC).Materials and Methods: Forty-one patients with EC and 21 women with uterine polyps were evaluated between January and December 2015 in aprospective study.Results: Age, body mass index, preoperative serum YKL-40 and CA 72-4 levels were significantly higher in the malignant group compared with the controlgroup. Serum YKL-40 levels were significantly higher in patients with superficial myometrial invasion and no lymph node involvement (p=0.042; p=0.004).No relationship between clinicopathologic factors and serum CA 72-4 levels was found.Conclusion: Serum CA 72-4 and YKL-40 levels are increased in women with EC compared with uterine polyps. Preoperative serum YKL-40 levels maybe associated with favorable prognostic factors. The determination of YKL-40 before surgery may be helpful in the evaluation of the regional lymph nodes.

Abstract

Amaç: Endometrial kanser (EC) tanısında YKL-40 ve kanser antijen (CA) 72-4 serum düzeylerinin prediktif rolünü belirlemektir. Gereç ve Yöntemler: Ocak-Aralık 2015 tarihleri arasında EC tanısı almış 41 hasta ve uterin polip tanısı almış 21 olgu prospektif olarak değerlendirildi. Bulgular: Yaş, vücut kitle indeksi, preoperatif serum YKL-40 ve CA 72-4 düzeyleri kontrol grubuna göre malign grupta anlamlı olarak yüksek bulundu. Serum YKL-40 düzeyleri, yüzeyel myometrial invazyonlu ve lenf nodu tutulumu olmayan olgularda anlamlı olarak yüksek saptandı (p=0,042; p=0,004). Klinikopatolojik faktörler ile serum CA 72-4 düzeyleri arasında ilişki bulunamadı. Sonuç: EC’li hastalarda serum CA 72-4 ve YKL-40 düzeyleri uterin polip saptanmış olgulara kıyasla artmıştır. Preoperatif serum YKL-40 seviyeleri, uygun prognostik faktörlerle ilişkili olabilir. YKL-40’ın cerrahi öncesi saptanması, bölgesel lenf nodlarının değerlendirilmesinde yardımcı olabilir.

🔖

Bu Makaleye Atıf Yap

KARATAŞ, S., SAL, V., KAHRAMANOĞLU, İ., DEMİRKIRAN, F., BEŞE, T., ARVAS, M., SOFİYEVA, N., GÜRALP, O., UZUN, H. (2018). Ykl-40 and cancer antigen 72-4 as new and promising diagnostic and prognostic markers for endometrial cancer. Turkish Journal of Obstetrics and Gynecology, Cilt: 15 - Sayı: 4, 235–242. https://ajindex.com/articles/376265

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. National Cancer Institute. Endometrial cancer treatment Physician Data Query (PDQ). 2015; http://www.cancer.gov/cancertopics/pdq/ treatment/endometrial/healthprofessional (1 April 2015, date last accessed). Ginath S, Menczer J, Fintsi Y, Ben-Shem E, Glezerman M, Avinoach I. Tissue and serum CA125 expression in endometrial cancer. Int J Gynecol Cancer 2002;12:372-75. Dotters DJ. Preoperative CA 125 in endometrial cancer: is it useful?. Am J Obstet Gynecol 2000;182:1328-34.
  2. Sood AK, Buller RE, Burger RA, Dawson JD, Sorosky JI, Berman M. Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome. Obstet Gynecol 1997;90:441-7.
  3. Brennan DJ, Hackethal A, Mann KP, Mutz-Dehbalaie I, Fiegl H, Marth C, et al. Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance. BMC Cancer 2015;15:33. Antonsen SL, Høgdall E, Christensen IJ, Lydolph M, Tabor A, Loft Jakobsen, et al. HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET). Acta Obstet Gynecol Scand 2013;92:1313-22.
  4. Yildiz A, Yetimalar H, Kasap B, Aydin C, Tatar S, Soylu F, et al. Preoperative serum CA 125 level in the prediction of the stage of disease in endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol 2012;164: 191-5.
  5. Mutz-Dehbalaie I, Egle D, Fessler S, Hubalek M, Fiegl H, Marth C, et al. HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol Oncol 2012;126:186-91.
  6. Renkema GH, Boot RG, Muijsers AO, Donker-Koopman WE, Aerts JM. Purification and characterization of human chitotriosidase, a novel member of the chitinase family of proteins. J Biol Chem 1995;270:2198-202.
  7. Tran A, Benzaken S, Saint-Paul MC, Guzman-Granier E, Hastier P, Pradier C, et al. Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease. Eur J Gastroenterol Hepatol 2000;12:989-93.
  8. Matsumoto T, Tsurumoto T. Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laboratory parameters. Clin Exp Rheumatol 2001;19:655-60.
  9. Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma, Cancer Res 2002;62:4364-8.
  10. Cintin C, Johansen JS, Christensen IJ, Price PA, Sørensen S, Nielsen HJ. Serum YKL-40 and colorectal cancer. Br J Cancer 1999;79:1494-9.
  11. Johansen JS, Drivsholm L, Price PA, Christensen IJ. High seru